by Lou Basenese | May 23, 2019 | CUE
Five key takeaways from Cue Biopharma’s Q1 2019 report, including the list of catalysts management believes will result in 2019 being a “transformational” year…
by Lou Basenese | May 16, 2019 | CUE
Here are three reasons why today’s FDA approval to enter the clinic with CUE-101 for HPV-associated cancers is significant, including two not so obvious reasons. Plus, a list of catalysts for 2019…
by Lou Basenese | Mar 14, 2019 | CUE
Here are the four keys to watch for when up-and-coming biotech Cue Biopharma (CUE) reports results today